SEC Form 4 · accession 0001209191-16-149900
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Biller
Officer — Chief Scientific Officer
Period of report
Nov 9, 2016
Accepted (ET)
Nov 14, 2016 · 6:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF2 | Nov 9, 2016 | S | 2,872 | $60.00 | D | 13,128 | I | See footnote |
| Common stockF2 | Nov 10, 2016 | S | 2,128 | $60.00 | D | 11,000 | I | See footnote |
| Common stock | holding | — | — | — | 48,270 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2Shares held by a spousal lifetime access trust, of which the reporting person's wife is trustee.